MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to NK Therapeutics' second quarter 2026 conference call and webcast. All participants will be in a listen-only mode until the question and answer session. Please note this event is being recorded. I would now like to turn the conference over to Stephanie Perdenacar from NK Therapeutics, NK Investor Relations. Stephanie, please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Dr. Terese Hammond, Head of Development, and Melissa Orilall, Principal Financial Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Dr. Buell? Thank you, Stephanie. Good morning, and thank you for joining us. The second quarter was an important period of execution for MNIC. We moved agent 797 into a randomized phase two study in patients with acute lung injury and ARDS. We presented initial day 28 observations from treated patients and established our first international paid named patient access program. Together, these reflect the model we are building, rigorous clinical development, rapid delivery of an off-the-shelf cell therapy, and Responsible Access for Patients with Urgent Unmet Needs. Critical illness is still treated largely by supporting failing organs while cli...